Bharat Biotech arm partners with VeGen Bio to develop India’s first dual-target CAR-T cell therapy
The story in brief
Bharat Biotech’s CRDMO arm Nucelion Therapeutics has partnered with Hyderabad-based VeGen Bio to develop VL-2511, India’s first dual-target CAR-T cell therapy for multiple myeloma. The collaboration aims to advance VL-2511 into Phase 1 and 2 trials and commercialise it by 2028, with Nucelion handling manufacturing at its GMP facility. The partnership seeks to improve manufacturing yields and make advanced cell therapies more accessible in India.